Physician profile
Chirag A Shah
NPI 1235248360
$731,981.39
in general payments reported to CMS, 2019-2025
21 companies · $86K in 2025
The $86K reported for 2025 was more than what 98% of Gynecologic Oncology providers received nationally (typical 2025 total: $305).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $145K · 2020: $34K · 2021: $38K · 2022: $94K · 2023: $153K · 2024: $182K · 2025: $86K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $276K · Consulting Fee: $63K · Travel and Lodging: $53K · Education: $20K · Food and Beverage: $8,957 · Gift: $17.64.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $275,906.50 |
| Consulting Fee | $63,024.00 |
| Travel and Lodging | $53,436.52 |
| Education | $19,564.50 |
| Food and Beverage | $8,956.61 |
| Gift | $17.64 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $234,089.30 | 2020-2025 | Jemperli, Zejula |
| Abbvie INC. | $120,685.31 | 2019-2025 | |
| Genmab U.S., INC. | $96,387.01 | 2023-2025 | Tivdak |
| Tesaro, INC. | $77,124.32 | 2019 | |
| Seagen INC. | $46,237.62 | 2021-2023 | Tivdak |
| Clovis Oncology, INC. | $40,228.00 | 2019-2021 | |
| Intuitive Surgical, INC. | $39,519.57 | 2020-2025 | Davinci Xi, Da Vinci Sp, Da Vinci Surgical System |
| Immunogen, INC. | $33,556.93 | 2023-2024 | Elahere, Elahere |
| Pfizer INC. | $18,522.66 | 2024-2025 | |
| Astrazeneca Pharmaceuticals Lp | $18,368.14 | 2019-2025 | Lynparza, Imfinzi |
| Medtronic, INC. | $2,696.65 | 2025 | Ligasure |
| Daiichi Sankyo INC. | $2,460.50 | 2025 | |
| Davol INC. | $694.54 | 2020-2021 | |
| Stryker Corporation | $451.81 | 2021 | |
| Myriad Genetic Laboratories, INC. | $278.24 | 2023-2024 | Mychoice Cdx, Precisetumor |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Johnson & Johnson Surgical Vision, INC. | $203.61 | 2023-2024 | Tecnis Iol, Tecnis Iol |
| Abbott Laboratories | $174.51 | 2023 | Cardiomems |
| Caris Mpi, INC. | $144.96 | 2025 | Mi Cancer Seek |
| Eisai INC. | $123.83 | 2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $33.88 | 2019-2020 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$4,140.00 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Chirag Shah listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.